The International Journal of Neuropsychopharmacology
September 1, 2026
Z. Li, D. Mukherjee, E. Dempster et al.
Abstract Background Adolescent cannabis use is associated with an increased risk of psychosis, yet the underlying molecular mechanisms remain poorly understood. Emerging evidence also pointed to genetic liability shaping individual risk of cannabis-induced psychosis. The neuregulin–ErbB4 signalling pathway, implicated in schizophrenia-related neurodevelopment, may modulate individual...
Psychological Medicine
November 1, 2024
L. Roldán, Teresa Sánchez‐Gutiérrez, I. Fernández-Arias et al.
Background Cannabis use and familial vulnerability to psychosis have been associated with social cognition deficits. This study examined the potential relationship between cannabis use and cognitive biases underlying social cognition and functioning in patients with first episode psychosis (FEP), their siblings, and controls. Methods We analyzed a sample of 543 participants with FEP, 203...
Psychological Medicine
May 9, 2024
J. Selten, Marta Di Forti, Diego Quattrone et al.
BACKGROUND We examined whether cannabis use contributes to the increased risk of psychotic disorder for non-western minorities in Europe. METHODS We used data from the EU-GEI study (collected at sites in Spain, Italy, France, the United Kingdom, and the Netherlands) on 825 first-episode patients and 1026 controls. We estimated the odds ratio (OR) of psychotic disorder for several groups of...
Translational Psychiatry
May 12, 2020
Chandni Hindocha, Diego Quattrone, Tom P. Freeman et al.
Epidemiological and biological evidence support the association between heavy cannabis use and psychosis. However, it is unclear which cannabis users are susceptible to its psychotogenic effect. Therefore, understanding genetic factors contributing to this relationship might prove an important strategy to identify the mechanisms underlying cannabis-associated psychotic experiences. We aimed to...
JAMA Psychiatry
April 8, 2020
R. Murray, W. Hall
There is a worldwide trend toward liberalizing cannabis policy and commercializing its sale. Uruguay legalized recreational cannabis in 2013, as did Canada in 2018, as well as 10 US states.1 Other countries have decriminalized the drug. In Holland, cannabis can be bought in designated cafes, and in Portugal, the police refer those who regularly use cannabis for counseling. Psychiatrists have...
Journal of dual diagnosis
January 2, 2020
Lucia Sideli, Harriet Quigley, Caterina la Cascia et al.
Abstract Objective: This review discusses the relationship between cannabis use and psychotic, bipolar, depressive, and anxiety disorders, as well as suicide. It summarizes epidemiological evidence from cross-sectional and long-term prospective studies and considers possible etiological mechanisms. Methods: Systematic reviews and methodologically robust studies in the field (from inception to...
Schizophrenia Bulletin
April 1, 2018
Freda Scheffler, S. Kilian, B. Chiliza et al.
Abstract Background Cannabis has been associated with higher risk to develop psychosis and worse long-term outcomes. Cannabis use in 2016 is estimated to be 11.3% in Chile in 2016 (SENDA 2016). As in many other countries, cannabis use has steadily increased during last 20 years, across all socioeconomic groups, but especially in men and in the group aged 12 to 25 years old. At the same time,...
Schizophrenia Bulletin
April 1, 2018
Marta Di Forti, Diego Quattrone, Giada Tripoli et al.
Abstract Background Cannabis use remains the most widely used recreational drug worldwide. Following from several USA states legalisation policies, European countries are reconsidering their cannabis laws. While a significant amount of Epidemiological evidence has reported that cannabis use increases the risk of psychosis it is still unclear: 1) what underpins individual differences in...
The Lancet Psychiatry
October 1, 2016
Tabea Schoeler, Natalia Petros, Marta Di Forti et al.
BACKGROUND Although cannabis use after a first episode of psychosis has been associated with relapse, little is known about the determinants of this most preventable risk factor for relapse of psychosis. Here we aimed to study whether the effects on outcome vary depending on the type of cannabis consumed and usage pattern. METHODS In this observational study, we prospectively recruited and...
The Lancet Psychiatry
March 1, 2016
Tabea Schoeler, Anna Monk, Musa Sami et al.
BACKGROUND Although the link between cannabis use and development of psychosis is well established, less is known about the effect of continued versus discontinued cannabis use after the onset of psychosis. We aimed to summarise available evidence focusing on the relationship between continued and discontinued cannabis use after onset of psychosis and its relapse. METHODS In this systematic...
European Psychiatry
2009
Paul D. Morrison, Shitij Kapur, R. Murray
1 citation
It has long been known that cannabis can elicit an acute psychotic reaction. Recent work shows that, of the 60 cannabinoid molecules in the plant, delta-9-tetrahydrocannibinol is responsible for the central effects of cannabis. Here we aimed to investigate, in more detail, the psychological effects of synthetic intravenous THC in healthy subjects. Over 2 experimental sessions, participants...